Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Completes Dosing of First Cohort in Phase IIb HBV Trial

Premium

Arrowhead Research announced this week that it has completed enrollment and dosing of the first cohort of patients in an ongoing Phase IIb trial of its hepatitis B drug ARC-520.

The open label, single ascending dose study is set to evaluate ARC-520 at doses of 1.0 mg/kg and 2.0 mg/kg. At each of the dose levels tested, 8 patients will be enrolled with 6 receiving ARC-520 and 2 receiving placebo.

The company reiterated its expectation that all patients will be dosed in the second quarter, with top-line results from the study available in the third quarter.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.